Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy
Authors:
- 16 May 2021
- journal article
- research article
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 58 (4) , 576-581
Abstract
Objective: Cytomegalovirus (CMV) maternal primary infection (MPI) in early pregnancy is the main risk factor for congenital CMV (cCMV) infection with long‐term sequelae. Our aim was to evaluate, in a single center offering CMV serology screening at 11–14 gestational weeks, secondary prevention of cCMV by administration of high‐dosage maternal oral valacyclovir (VACV) in the first trimester of pregnancy.Methods: This was a case–control study in a longitudinal cohort of pregnancies with CMV‐MPI diagnosed prior to 14 weeks of gestation by serology screening (immunoglobulin (Ig) M and IgG measurement and IgG avidity) between 2009 and 2020. From October 2019 onwards, all women presenting at our center with MPI before 14 weeks' gestation were offered treatment with high‐dosage oral VACV (8 g/day, 4 g twice/day). We used propensity score matching to compare fetal infection rates in cases treated with maternal oral VACV (8 g/day) with those in untreated controls. Fetal infection was assessed following amniocentesis at 17–22 weeks of gestation, by polymerase chain reaction (PCR) analysis of amniotic fluid for viral DNA.Results: Of 310 cases of CMV‐MPI identified, 269 underwent amniocentesis for PCR. Of these, 66 were offered, and 65 accepted, treatment with VACV. From the remaining untreated cases, we selected 65 controls, matched for proportion of periconceptional infections and gestational age at amniocentesis. VACV was initiated at a median gestational age of 12.71 (interquartile range (IQR), 10.00–13.86) weeks and the median duration of treatment was 35 (IQR, 26–54) days. On multivariate logistic regression, fetal infection was lower in the treated group (odds ratio, 0.318 (95% CI, 0.120–0.841); P = 0.021). One treated patient developed acute renal failure 4 weeks after initiation of VACV therapy, but this resolved within 5 days after treatment was stopped.Conclusion: This study confirms the acceptability, tolerance and benefit of secondary prevention by VACV of cCMV infection in a clinical setting with a well‐established routine maternal serum screening policy in the first trimester of pregnancy. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.Keywords
This publication has 22 references indexed in Scilit:
- In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II studyAmerican Journal of Obstetrics and Gynecology, 2016
- Diagnosis and antenatal management of congenital cytomegalovirus infectionAmerican Journal of Obstetrics and Gynecology, 2016
- Clinical Implications for Children Born With Congenital Cytomegalovirus Infection Following a Negative AmniocentesisClinical Infectious Diseases, 2016
- Evaluation of the new LIAISON ® CMV IgG, IgM and IgG Avidity II assaysJournal of Clinical Virology, 2015
- Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assayEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ TransplantationTransplantation, 2013
- Re-evaluation of the VIDAS® cytomegalovirus (CMV) IgG avidity assay: Determination of new cut-off values based on the study of kinetics of CMV–IgG maturationJournal of Clinical Virology, 2013
- Matching Methods for Causal Inference: A Review and a Look ForwardStatistical Science, 2010
- Congenital cytomegalovirus infection following first trimester maternal infection: Symptoms at birth and outcomeJournal of Clinical Virology, 2006
- Renal tubular transporters and antiviral drugs: an updateAIDS, 2005